A tale of two alleles: TP53 and transformation in MPNs

In this issue of Blood, Li et al harness an elegant series of preclinical models to address 3 questions in the biology of myeloproliferative neoplasms (MPNs). They ask how the TP53 allelic state promotes leukemic transformation; what the cellular origin of the resultant leukemia is; and whether the TP53 mutant clones bear specific vulnerabilities amenable to therapeutic exploitation.(1)